Sodium glucose cotransporter 2 inhibitors (SGLT-2I), an inhibitor of a new pathway of HF treatment different from the neurohormonal one, are associated with reduced HF hospitalizations and CV death in patients with type 2 diabetes mellitus regardless of history of HF (24, 25), and the ongoing EMPEROR-Preserved, DELIVER, and SOLOIST-WHF trials may confirm the effect of these drugs on HF outcomes in patients with LVEF >45%. Here, SLC5A2 is linked to hydrops fetalis.